Drug Landscape ›
Diphenhydramine 25mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 147
Most-reported reactions
Infusion Related Reaction — 40 reports (27.21%) Dyspnoea — 17 reports (11.56%) Nausea — 17 reports (11.56%) Pruritus — 15 reports (10.2%) Headache — 13 reports (8.84%) Urticaria — 12 reports (8.16%) Flushing — 10 reports (6.8%) Rash — 8 reports (5.44%) Vomiting — 8 reports (5.44%) Diarrhoea — 7 reports (4.76%)
Source database →
Diphenhydramine 25mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Diphenhydramine 25mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Diphenhydramine 25mg in United States?
Montefiore Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.